Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENEKA Study
2024-513971-42-00Phase 3Completed
- Sponsor
- Hospital Clínico Universitario de Valencia
- Start
- Oct 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sodium zirconium cyclosilicate in chronic heart failure (CHF), chronic kidney disease (CKD) and hyperkalemia (2 arms), sponsored by Hospital Clínico Universitario de Valencia. Primary endpoint: Increase of at least 25% of target RAAS inhibitor dose by 3 months. Started Oct 2024; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
chronic heart failure (CHF)chronic kidney disease (CKD)hyperkalemia
Beyond the preview
Go deeper on 2024-513971-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513971-42-00.